5 Considerations For Obviousness-Type Double Patenting
On Oct. 7, the U.S. Supreme Court denied certiorari for In re: Cellect. As it stands, In re: Cellect and the Aug. 13 decision in Allergan USA Inc. v. MSN Laboratories...To view the full article, register now.
Already a subscriber? Click here to view full article